SG11201803808VA - 1,3,4-thiadiazole compounds and their use in treating cancer - Google Patents
1,3,4-thiadiazole compounds and their use in treating cancerInfo
- Publication number
- SG11201803808VA SG11201803808VA SG11201803808VA SG11201803808VA SG11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA SG 11201803808V A SG11201803808V A SG 11201803808VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- astrazeneca
- cambridge
- park
- cheshire
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau ... ......*eid C.,,,,1 (43) International Publication Date 0 8 June 2017 (08.06.2017) WI P0 I P CT ID Hit (10) 11111111111111111111 WO International Ell 2017/093301 11111111111111111111 Publication 11111 Number Al HIRE IIII IIIIIIII (51) International Patent Classification: Way, Macclesfield Cheshire SK10 2NA (GB). BAILEY, C07D 417/14 (2006.01) A61P 35/00 (2006.01) Andrew; AstraZeneca Alderley Park, Macclesfield A61K 31/433 (2006.01) Cheshire SK10 4TG (GB). (21) International Application Number: (74) Agent: COOK, Andrew; AstraZeneca Intellectual Prop - PCT/EP2016/079253 erty Mereside, Alderley Park, Macclesfield Cheshire SK10 4TG (GB). (22) International Filing Date: 30 November 2016 (30.11.2016) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (26) Publication Language: English BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (30) Priority Data: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/260784 30 November 2015 (30.11.2015) US KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicants: ASTRAZENECA AB [SE/SE]; 151 85 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Sodertalje (SE). CANCER RESEARCH TECHNO- OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, LOGY LIMITED [GB/GB]; Angel Building 407 St John SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, Street, London EC1V 4AD (GB). TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: FINLAY, Maurice, Raymond, Verschoyle; AstraZeneca R&D Cambridge, Darwin Building Cam- (84) Designated States (unless otherwise indicated, for every bridge Science Park, Milton Road, Cambridge Cambridge- kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, shire CB4 OFZ (GB). PERKINS, David, Robert; As- TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, tra7eneca Block 11S, Mereside, Alderley Park, Maccles- field Cheshire SK10 4TG NISSINK, Johannes, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (GB). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, Wilhelmus, Maria; AstraZeneca, Darwin Building Cam- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Science Park, Milton Road, Cambridge Canbridge- TR), BJ, SM, OAPI (BF, CF, CG, CI, CM, GA, GN, GQ, shire CB4 OWG (GB). RAUBO, Piotr, Antoni; As SM, GW, KM, ML, MR, NE, SN, TD, TG). tra7eneca, Hodgkin Building, Chesterford Research Cam- pus Little Chesterford, Saffron Walden, Cambridge Cam- Published: bridgeshire CB10 1XL (GB). SMITH, Peter, Duncan; As- with international search report (Art 21(3)) traZeneca, Early Chemical Development, Pharmaceutical Sciences Etherow F40/4, Silk Road Business Park, Charter (54) Title: 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER R3 , R2 R 1 H H S N 1-1 _ s\ r ....„. I R 4 .4t 1-1 o en M Q C\ 0 N 1-1 (57) : A compound of Formula O fluoropyridazin-3-y1; R 1 can be H; \" and R 2 taken together can be -(CH2)2- 0 The compound of formula (I) can inhibit R 2 and and R 3 can each R 3 can be glutaminase, (I) or a pharmaceutically N—N -CH3; e.g., independently R 4 halo, GLS1. acceptable be Cl-C6 -CH3, -OCH3, / salt thereof, is described. alkyl, or -OCHF2, R 2 and R 3 taken -OCF3, or (J) Q can be pyridazin-3-yl, 6- together are -(CH 2 ) 3 ; or R 1 -CN; and n can be 0, 1, or 2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562260784P | 2015-11-30 | 2015-11-30 | |
| PCT/EP2016/079253 WO2017093301A1 (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803808VA true SG11201803808VA (en) | 2018-06-28 |
Family
ID=57460503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803808VA SG11201803808VA (en) | 2015-11-30 | 2016-11-30 | 1,3,4-thiadiazole compounds and their use in treating cancer |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10040789B2 (en) |
| EP (1) | EP3383872B1 (en) |
| JP (1) | JP6821680B2 (en) |
| KR (1) | KR20180083411A (en) |
| CN (1) | CN108349965B (en) |
| AR (1) | AR106875A1 (en) |
| AU (1) | AU2016361834B2 (en) |
| BR (1) | BR112018008330B1 (en) |
| CA (1) | CA3005517C (en) |
| CL (1) | CL2018001409A1 (en) |
| CO (1) | CO2018006930A2 (en) |
| DK (1) | DK3383872T3 (en) |
| DO (1) | DOP2018000135A (en) |
| EA (1) | EA035519B9 (en) |
| ES (1) | ES2796562T3 (en) |
| IL (1) | IL259508A (en) |
| MX (1) | MX2018006483A (en) |
| MY (1) | MY195680A (en) |
| NI (1) | NI201800063A (en) |
| NZ (1) | NZ743699A (en) |
| PE (1) | PE20181522A1 (en) |
| PH (1) | PH12018501133A1 (en) |
| SG (1) | SG11201803808VA (en) |
| SV (1) | SV2018005700A (en) |
| TN (1) | TN2018000118A1 (en) |
| TW (1) | TW201731511A (en) |
| WO (1) | WO2017093301A1 (en) |
| ZA (1) | ZA201804361B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201520959D0 (en) | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201730188A (en) | 2015-11-30 | 2017-09-01 | 阿斯特捷利康公司 | 1,3,4-thiadiazole compounds and their use in treating cancer |
| TW201733587A (en) | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-thiadiazole compounds and their use in treating cancer |
| WO2020078350A1 (en) * | 2018-10-16 | 2020-04-23 | 南京明德新药研发有限公司 | Thiadiazole derivative and uses thereof as a gls1 inhibitor |
| CN114560855B (en) * | 2021-03-26 | 2023-05-23 | 成都苑东生物制药股份有限公司 | Cycloalkyl carboxamide derivatives, preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201402305WA (en) | 2011-11-21 | 2014-06-27 | Calithera Biosciences Inc | Heterocyclic inhibitors of glutaminase |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| WO2014079011A1 (en) * | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US20160297761A1 (en) | 2014-01-06 | 2016-10-13 | Rhizen Pharmaceuticals Sa | Novel inhibitors of glutaminase |
| GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
-
2016
- 2016-11-29 TW TW105139334A patent/TW201731511A/en unknown
- 2016-11-29 US US15/362,989 patent/US10040789B2/en active Active
- 2016-11-30 MY MYPI2018702070A patent/MY195680A/en unknown
- 2016-11-30 ES ES16805078T patent/ES2796562T3/en active Active
- 2016-11-30 JP JP2018527201A patent/JP6821680B2/en active Active
- 2016-11-30 MX MX2018006483A patent/MX2018006483A/en unknown
- 2016-11-30 AU AU2016361834A patent/AU2016361834B2/en active Active
- 2016-11-30 EA EA201891239A patent/EA035519B9/en not_active IP Right Cessation
- 2016-11-30 PE PE2018001012A patent/PE20181522A1/en unknown
- 2016-11-30 AR ARP160103664A patent/AR106875A1/en unknown
- 2016-11-30 DK DK16805078.9T patent/DK3383872T3/en active
- 2016-11-30 TN TNP/2018/000118A patent/TN2018000118A1/en unknown
- 2016-11-30 SG SG11201803808VA patent/SG11201803808VA/en unknown
- 2016-11-30 KR KR1020187017163A patent/KR20180083411A/en unknown
- 2016-11-30 CA CA3005517A patent/CA3005517C/en active Active
- 2016-11-30 NZ NZ743699A patent/NZ743699A/en unknown
- 2016-11-30 CN CN201680067210.XA patent/CN108349965B/en active Active
- 2016-11-30 WO PCT/EP2016/079253 patent/WO2017093301A1/en active Application Filing
- 2016-11-30 BR BR112018008330-5A patent/BR112018008330B1/en active IP Right Grant
- 2016-11-30 EP EP16805078.9A patent/EP3383872B1/en active Active
-
2018
- 2018-05-22 IL IL259508A patent/IL259508A/en active IP Right Grant
- 2018-05-24 CL CL2018001409A patent/CL2018001409A1/en unknown
- 2018-05-29 PH PH12018501133A patent/PH12018501133A1/en unknown
- 2018-05-29 DO DO2018000135A patent/DOP2018000135A/en unknown
- 2018-05-29 SV SV2018005700A patent/SV2018005700A/en unknown
- 2018-05-29 NI NI201800063A patent/NI201800063A/en unknown
- 2018-06-28 ZA ZA2018/04361A patent/ZA201804361B/en unknown
- 2018-06-29 CO CONC2018/0006930A patent/CO2018006930A2/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803808VA (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201908598PA (en) | Compounds useful in the treatment or prevention of a prmt5-mediated disorder | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201805838UA (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| SG11201908532UA (en) | Macrocyclic compounds as ros1 kinase inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201809342YA (en) | Pyrimidine compounds as jak kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201810970WA (en) | Anti-egfr antibody drug conjugates | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201805154YA (en) | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof | |
| SG11201804123VA (en) | Modulators of kv3 channels to treat pain | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201903348UA (en) | Therapeutic compounds and methods of use thereof | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201811380RA (en) | Chelate compounds | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors |